NewslettersHematopoiesis NewsUncategorizedVOR33 Granted US FDA Fast Track Designation for AMLBy Justin.choi - September 9, 2021051Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, the company’s lead engineered HSC therapeutic candidate for the treatment of acute myeloid leukemia (AML).[Vor Biopharma] 7992332 {7992332:nan} apa 50 1 166610 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Press Release